ALXN - アレクション・ファ―マシュ―ティカルズ （Alexion Pharmaceuticals Inc.）ALXNのニュース
ICER finds Alexion''s Soliris lacks cost-effectiveness for myasthenia gravis 2021/07/22 14:09:02 Seeking Alpha
Acquisition of Alexion completed 2021/07/21 18:43:02 CompanyNewsHQ
21 July 2021 13:45 BST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN View post on CompanyNewsHQ : Acquisition of Alexion completed
Samson Rock Capital LLP Buys Proofpoint Inc, Alexion Pharmaceuticals Inc, Nuance Communications ... 2021/07/20 20:38:09 GuruFocus
Related Stocks: ALXN , WORK , XLNX , PFPT , NUAN , WLTW , PPD , KSU , QTS , VAR , RP , GLUU , WIFI , CLGX , PS ,
Alexion''s Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms 2021/07/20 18:37:04 Benzinga
Ultomiris, the successor to Alexion Pharmaceuticals Inc''s (NASDAQ: ALXN ) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year. The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing , a whopping 48% Full story available on Benzinga.com